[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Illinois at Chicago\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":582},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,132,0,25,[9,46,66,91,115,138,165,185,205,225,244,262,279,298,325,347,371,401,425,445,476,494,517,539,558],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100053392",false,"NCT06410261","Exercise Rehabilitation Program in MS Who Use Wheelchairs as a Primary Mobility Device","Randomized Pilot Study Evaluating the Effect of a 6-Month Exercise Rehabilitation Program on Physical and Cognitive Function in Persons With MS Who Use Wheelchairs as a Primary Mobility Device","MSGH","Inclusion Criteria:\n\n* diagnosis of MS\n* age above 18 years\n* no relapse within last 30 days\n* use of wheelchair for mobility in the community\n* ability to walk at least 50 feet (or 65 steps) using an assistive device\n* low risk for contraindications of physical activity indicated by no more than a single \"yes\"\n* response on the Physical Activity Readiness Questionnaire (PAR-Q)\n* willingness to complete the assessments and undergo randomization\n\nExclusion Criteria:\n\n* no diagnosis of MS\n* less than 18 years of age\n* not relapse-free within the last 30 days\n* no use of wheelchair as primary mobility device\n* no ability to walk for at least 50 feet (or 65 steps)\n* high risk for contraindications based on more than a single \"yes\" response on the PAR-Q\n* not willing to complete the testing procedures and undergo randomization","ALL","18 Years",{"count":20,"type":21},24,"ESTIMATED","INTERVENTIONAL",[24],"NA","Approximately 50% of people with multiple sclerosis (MS) use a wheelchair within 30 years of the initial diagnosis. Wheelchair use in MS is often associated with fatigue as a consequence of muscle weakness. Indeed, fatigue, a prevalent consequence of MS, often becomes debilitating and exhausts energetic resources when carrying-out tasks of daily life and\u002For interacting with the community, as these require ambulatory mobility. This experience of excessive fatigue has its roots in muscle weakness and results in reliance on a wheelchair for mobility, and the dependency on a wheelchair may further reduce muscular strength, particularly of the lower extremities. We propose that wheelchair users with MS can increase muscular strength through a personalized exercise rehabilitation, and this in turn will improve ambulatory performance and possibly reduce fatigue. To date, no research has examined the effects of this specific exercise rehabilitation program (GH method) on physical function and other disease-related outcomes in persons with MS who use wheelchairs as a primary mobility device.",[27],"Multiple Sclerosis",[29,30,31,32],"Exercise","Rehabilitation","Physical function","Cognition","RECRUITING","2026-07-10",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":37},"2024-04-29",{"date":41,"type":21},"2027-07-31",{"name":43,"class":44},"University of Illinois at Chicago","OTHER",1,{"id":47,"slug":4,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":45},"100053622","NCT07695948","Effects, Metabolic Mechanisms and Predictors of Response to Acupuncture in Treating Psychoneurological Symptoms Among Breast Cancer Survivors","Inclusion Criteria:\n\n* ≥ 18 years of age\n* With histologically confirmed Stage 0-III ER\u002FPR-positive HER2-negative breast cancer\n* Currently receiving adjuvant endocrine therapy\n* Completed their primary cancer treatment (e.g., surgery, radiotherapy, chemotherapy) at least 3 months prior to recruitment\n* Acupuncture-naïve\n* Have self- reported pain, fatigue, and sleep disturbance in the last month with an average severity rating ≥ 3 (0-10 numeric rating scale) for at least 2 of the 3 symptoms.\n\nExclusion Criteria:\n\n* Taking methylsulfonylmethane or glutathione supplements\n* Physically or cognitively unable to complete the study procedures\n* Pregnant","FEMALE",{"count":53,"type":21},252,[55],"PHASE3","The purpose of this study is to examine the effect, mediators and predictors of treatment response of acupuncture in treating the psychoneurological symptom cluster (pain, fatigue, sleep disturbance) among breast cancer survivors.",[58],"Breast Cancer","NOT_YET_RECRUITING",{"date":36,"type":37},{"date":62,"type":21},"2026-09-01",{"date":64,"type":21},"2031-08-31",{"name":43,"class":44},{"id":67,"slug":4,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":17,"minAge":72,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":22,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":45},"100561509","NCT06591091","Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression","CLIMB","Inclusion Criteria:\n\n* Age \\> 60 years\n* Diagnosis of major depressive disorder, single or recurrent episode (DSM5)\n* Symptom Severity: MADRS ≥ 15\n* Seeking antidepressant treatment\n* Cognition score of MoCA \\>24\n* Fluent in English or Spanish\n\nExclusion Criteria:\n\n* Other Axis I psychiatric disorders, except for simple phobia or anxiety disorders present uniquely during the depressive episode (e.g., generalized anxiety disorder (GAD) or panic disorder symptoms)\n* History of alcohol or drug dependence or abuse in the last year\n* History of a developmental disorder or history of IQ (intelligence quotient) \\\u003C70\n* Acute suicidality ideation within the past month as determined by the Columbia Suicide Severity Rating Scale (C-SSRS)\n* Acute grief (\\\u003C1 month)\n* Current or past psychosis\n* Primary neurological disorder, including dementia, clinical stroke, brain tumor, epilepsy, etc.\n* Presence of unstable medical illness requiring urgent treatment\n* Any MRI contraindication\n* Electroconvulsive Therapy (ECT) in last 6 months","60 Years",{"count":74,"type":21},80,[76],"PHASE2","The goal of this study is to find out if the antihistamine, clemastine, can make the white matter in the brain better in older adults with depression. The study will also determine whether this improvement can make antidepressant treatment work better, reduce depressive symptoms, and improve memory and thinking.",[79],"Depression",[81,82],"Late-life Depression","Antidepressant medication response","2026-06-26",{"date":85,"type":37},"2026-06-30",{"date":87,"type":37},"2025-12-10",{"date":89,"type":21},"2026-12",{"name":43,"class":44},{"id":92,"slug":4,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":100,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":45},"100564044","NCT06624046","Circadian Mechanisms, Glucose, and CV Risks in T1D","Circadian Mechanisms of Glycemic Control and Cardiovascular Risk in Adults With Type 1 Diabetes","Inclusion Criteria:\n\n* Adults 18-50 years with a clinical diagnosis of T1D for at least one year\n* Report habitual sleep irregularity ≥1 hour\u002Fweek\n* Desire to improve sleep, and own a smartphone (Android or iPhone)\n\nExclusion Criteria:\n\n* Self-reported A1C within the past 6 months ≥10%\n* insomnia symptoms defined as Insomnia Severity Index score ≥15\n* history of restless leg syndrome\n* history of severe hypoglycemia (defined as hypoglycemic episode that results in loss of consciousness, seizure, or requiring emergency room visit or hospitalization) within the past 6 months\n* rotating shift or night work or routinely sleeping after 3 AM.\n* use of sleep medications\u002Faids, significant medical comorbidities (such as heart failure, cirrhosis, chronic obstructive pulmonary disease requiring oxygen, active treatment for cancer, on renal replacement therapy \\[dialysis\\])\n* depression (Patient Health Questionnaire 8 \\[PHQ-8\\] score ≥15)\n* history of stroke with neurological deficits\n* pregnant, breast feeding, or planning pregnancy, as sleep and glucose are known to change during pregnancy and breastfeeding.\n* Allergy to lidocaine Participants who passed the first screen by phone will be scheduled for a consenting visit at UIC","50 Years",{"count":99,"type":21},100,[24],"People with type 1 diabetes are disproportionately affected by cardiovascular disease (CVD). Short and irregular sleep have been associated with cardiovascular risk in this population. Improving sleep regularity has been associated with improved glycemic markers however mechanisms by which improving sleep regularity improves metabolic and cardiovascular health is not known. The investigators propose to conduct a mechanistic study using a sleep stability manipulation. This proposal will advance the understanding of mechanisms by which improving sleep regularity influences glycemic control and cardiovascular risk in T1D.",[103],"Type 1 Diabetes (T1D)",[105,106,107],"sleep","cardiovascular disease risk","glycemic control","2026-06-25",{"date":85,"type":37},{"date":111,"type":37},"2025-03-13",{"date":113,"type":21},"2029-08-31",{"name":43,"class":44},{"id":116,"slug":4,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":121,"sex":17,"minAge":122,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":45},"100644756","NCT07674303","Multi-Site Feasibility Testing a Meditation App for Youth in the Legal System","Improving Psychological Wellbeing and Decreasing Psychological Distress Among Youth in the Legal System: Multi-Site Feasibility Trial of a Mindfulness Meditation App","Inclusion Criteria:\n\n* 13-20 years old\n* In probation or related programming (i.e., in legal programming but not detained) in Oregon or New York State\n* Have access to an Apple\u002FAndroid smartphone\n* Understand and provide assent\u002Fconsent\n* Have legal guardian permission (if under 18 years old)\n* English-speaking, due to norming of instruments\n\nExclusion Criteria:\n\n\\- There are no exclusion criteria.",true,"13 Years","20 Years",{"count":125,"type":21},120,[24],"This multi-site feasibility clinical trial aims to assess the feasibility of implementing a 1-month app-based meditation program with youth in 4 heterogeneous juvenile legal systems across Oregon and New York. The primary question it is designed to answer is: Will youth adequately adhere to the 1-month meditation app across sites? Secondary feasibility outcomes pertain to recruitment, randomization, retention, and survey completion.",[129],"Behavioral Health","2026-06-23",{"date":132,"type":37},"2026-06-29",{"date":134,"type":21},"2026-07",{"date":136,"type":21},"2028-06",{"name":43,"class":44},{"id":139,"slug":4,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":148,"briefSummary":149,"conditions":150,"keywords":155,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":159,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":45},"100577747","NCT06802315","Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)","A Phase II Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Myeloablative Fludarabine\u002FBusulfan and Post-Transplant Cyclophosphamide (PTCY) for Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk AML, CML, and MDS","BMT-13","Inclusion Criteria:\n\n* 1\\. Age 18-65 years.\n* 2\\. Patients with CML, AML, or MDS who meet one of the following criteria: 2a. Relapsed or refractory AML (including AML in CR2) 2b. Poor-risk AML in first remission, with remission defined as \\\u003C5% bone marrow blasts morphologically:\n* AML arising from MDS, a myeloproliferative disorder, or secondary AML\n* Poor risk molecular features according to Leukemia Net including ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and\u002For ZRSR2\n* Poor-risk cytogenetics: Monosomal karyotype, complex karyotype (\\> 3 abnormalities), inv (3), t(3;3), t(6;9), MLL rearrangement with the exception of t(9;11), or abnormalities of chromosome 5 or 7. 2c. Primary refractory disease 2d. MDS with at least one of the following poor-risk features:\n* Poor-risk cytogenetics including 3q abnormalities, 7\u002F7q minus or complex cytogenetics (\\>3 abnormalities).\n* Current or previous INT-2 or high IPSS score.\n* Treatment-related MDS.\n* MDS diagnosed before the age of 21 years.\n* Progression on or lack of response to standard DNA-methyltransferase inhibitor therapy.\n* Life-threatening cytopenias, including those requiring regular PRBC or platelet transfusions. 2e. CML with a history of accelerated or blast phase.\n\nExclusion Criteria:\n\n* 1\\. Presence of significant co-morbidity as shown by:\n* 1a. Left ventricular ejection fraction \\\u003C 50%\n* 2b. Creatinine clearance \\\u003C30ml\u002Fmin.\n* 3c. Bilirubin \\> 2.0 mg\u002FdL (unless due to Gilbert's syndrome or hemolysis), and ALT and AST \\> 5 x ULN.\n* 4d. FEV1 and FVC \\\u003C 50% of predicted or DLCO \\\u003C50% of predicted once corrected for anemia.\n* 5e. Karnofsky score \\\u003C70\n* 6f. Active viral hepatitis or HIV infection.\n* 7g. Cirrhosis.\n* 2\\. Pregnancy or breast feeding\n* 3\\. Patients unable to sign informed consent.\n* 4\\. Patients previously received radiation to \\>20% of bone marrow-containing areas.","65 Years",{"count":147,"type":21},38,[76],"The study is a Phase II clinical trial. Patients will receive intensity-modulated total marrow irradiation (TMI) at a dose of 9 Gray (Gy) with standard myeloablative fludarabine intravenous (IV) and targeted busulfan (FluBu4) conditioning prior to allogeneic hematopoietic stem cell transplant (HSCT). Graft-versus-host disease (GVHD) prophylaxis will include Cyclophosphamide on Day +3 and +4, tacrolimus, and mycophenolate mofetil.",[151,152,153,154],"Acute Myeloid Leukemia, Relapsed, Adult","Acute Myeloid Leukemia Refractory","Chronic Myeloid Leukemia - Accelerated Phase","Myelodysplastic Syndromes",[156,157,158],"Total Marrow Irradiation","Stem Cell Transplant","Allogenic Transplant",{"date":83,"type":37},{"date":161,"type":37},"2025-02-04",{"date":163,"type":21},"2032-03",{"name":43,"class":44},{"id":166,"slug":4,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":22,"phases":173,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":182,"leadSponsor":184,"locationsCount":45},"100641946","NCT07647250","Pilot Study to Evaluate Targeted Physical Activity Among Pancreatic Cancer Patients Receiving Neoadjuvant Chemotherapy","Pilot Study Evaluating the Impact of Targeted Physical Activity Among Frail Pancreatic Cancer Patients Receiving Neoadjuvant Chemotherapy","GI-07","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Diagnosis of pancreatic cancer that is potentially resectable per the treating clinical team's assessment.\n3. Planned to receive or actively receiving neoadjuvant chemotherapy prior to surgery.\n4. Frail or pre-frail as defined by the protocol-specified frailty assessment tool (e.g., Fried Frailty Phenotype; pre-frail = 1-2 criteria; frail =\\> 3 criteria).\n5. Able to provide written informed consent.\n6. Medically appropriate to participate in supervised, symptom-limited exercise as determined by study screening and, if indicated, the treating clinician's input.\n7. Able to complete study assessments and questionnaires in English or Spanish (using IRB- approved instruments\u002Fmaterials).\n\nExclusion Criteria:\n\n1. Adults unable to consent.\n2. Medical condition that, in the judgment of the investigator and\u002For treating clinician, makes exercise unsafe (e.g., unstable angina, uncontrolled arrhythmia, decompensated heart failure, uncontrolled severe pulmonary disease).\n3. Any absolute contraindication to exercise participation\u002Ftesting per institutional standards.\n4. Severe symptoms or functional impairment that prevents safe participation despite program modification.\n5. Inability to comply with the intervention schedule and study procedures despite reasonable scheduling accommodations.",{"count":7,"type":21},[24],"Patients with pancreatic cancer receiving neoadjuvant chemotherapy often experience functional decline, treatment interruptions, and clinical deterioration, and these risks may be amplified when frailty is present.",[176,177],"Physiological Reactivity to Cues","Physical Exercise","2026-06-22",{"date":180,"type":37},"2026-06-24",{"date":178,"type":37},{"date":183,"type":21},"2032-04-30",{"name":43,"class":44},{"id":186,"slug":4,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":22,"phases":193,"briefSummary":195,"conditions":196,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":204},"100529099","NCT06169371","Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)","BRE-09","Inclusion Criteria:\n\n* ECOG 0-2\n* Histologically confirmed early-stage HR+HER2- breast cancer documented by biopsy who are prescribed adjuvant abemaciclib\n* Able to provide written informed consent and HIPAA authorization for release of personal health information, via an approved UIC Institutional Review Board (IRB) informed consent form and HIPAA authorization.\n* Women of childbearing potential must not be pregnant or breast-feeding. A negative serum or urine pregnancy test is required per institutional practice guidelines.\n* As determined at the discretion of the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study.\n\nExclusion Criteria:\n\n* Chronic history of diarrhea\n* Active infection requiring systemic therapy\n* Uncontrolled HIV\u002FAIDS or active viral hepatitis\n* Pregnant or nursing\n* Any prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of this investigational regimen, as determined by the treating medical oncologist.\n* Other major comorbidity as determined by study PI",{"count":192,"type":21},50,[194],"PHASE4","This is a post-marketing single arm, phase IV trial in which patients with high-risk early-stage HR+HER2- breast cancer will receive adjuvant abemaciclib in combination with endocrine therapy (ET) After study intervention, participants will remain on combination abemaciclib + ET at the discretion of their treating providers",[58],"2026-06-18",{"date":130,"type":37},{"date":200,"type":37},"2023-12-28",{"date":202,"type":21},"2030-11",{"name":43,"class":44},3,{"id":206,"slug":4,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":22,"phases":213,"briefSummary":214,"conditions":215,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":219,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":45},"100430898","NCT04891068","BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer","BRE-04","Inclusion Criteria:\n\n1. Age ≥ 18 years of age at time of consent\n2. ECOG 0, 1, or 2\n3. Histologically confirmed invasive breast carcinoma documented by biopsy. AJCC 8th edition clinical stage T1a-T3\u002FN0-N1\u002FM0 by physical exam or radiologic studies\n4. Disease characteristics I. TNBC (Less than or equal to 10% of tumor cells staining for ER and for PR by immunohistochemistry (IHC). HER2-negative, as defined by ASCO\u002FCAP guidelines)\n\nOR\n\nII. ER positive (as determined by immunohistochemistry (IHC)) and any of the following high risk characteristics:\n\n1. HER2 positive (IHC or FISH)\n2. Node positive\n3. Any clinical high-risk expression profile (mammaprint, oncotype, endopredict)\n4. PR negative (IHC) OR III. HER 2 positive (as defined by ASCO\u002FACP guidelines) f. Demonstrates adequate organ function as defined in table below. All screening labs to be obtained within 30 days prior to registration.\n\nSystem Laboratory Value Hematological Leukocytes ≥3,000\u002Fmm3 Platelet count ≥ 100,000\u002Fmm3 Absolute Neutrophil Count (ANC) ≥ 1,500\u002Fmm3 Hemoglobin (Hgb) ≥ 9.0 g\u002FdL Renal Creatinine\u002FCalculated creatinine clearance (CrCl) Cr \\\u003C 1.5 x upper limit of normal (ULN) or CrCl ≥ 50 mL\u002Fmin using the Cockcroft-Gault formula Hepatic Bilirubin Bilirubin ≤ 1.5 × ULN. Subjects with Gilbert's syndrome may have a bilirubin \\> 1.5 × ULN, if no evidence of biliary obstruction exists Aspartate aminotransferase (AST) ≤ 2.5 × ULN Alanine aminotransferase (ALT) ≤ 2.5 × ULN g. No evidence of distant metastases (M0 per AJCC staging guidelines) h. Provided written informed consent and HIPAA authorization for release of personal health information, via an approved UIC Institutional Review Board (IRB) informed consent form and HIPAA authorization.\n\ni. Women of childbearing potential must not be pregnant or breast-feeding. A negative serum or urine pregnancy test is required per institutional practice guidelines.\n\nj. As determined at the discretion of the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study.\n\nExclusion Criteria:\n\n1. Previous anti-cancer treatment (cytotoxic chemotherapy, immunotherapy, biologic therapy, radiotherapy directed towards the primary breast tumor and\u002For ipsilateral axillary lymph nodes or investigational agents) with therapeutic intent for the current breast cancer.\n2. Any type of breast implants\n3. Active infection requiring systemic therapy\n4. Uncontrolled HIV\u002FAIDS or active viral hepatitis\n5. Pregnant or nursing\n6. Any prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of this investigational regimen, as determined by the treating medical oncologist.\n7. Any mental or medical condition that prevents the patient from giving informed consent or participating in the trial unless a Legal Authorized Representative (LAR) is in place to sign on behalf of the patient.\n8. Other major comorbidity, as determined by study PI",{"count":212,"type":21},40,[76],"To determine the effect of low dose azacitidine therapy on tumor infiltrating lymphocytes (TILs) in primary tumors from patients with high-risk early stage breast cancer, paired t-tests will be first used to compare TIL count in pre- and post-treatment specimens.",[216,217,218],"Breast Cancer Invasive","Early-stage Breast Cancer","High Risk Breast Carcinoma",{"date":130,"type":37},{"date":221,"type":37},"2022-01-10",{"date":223,"type":21},"2027-05",{"name":43,"class":44},{"id":226,"slug":4,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":22,"phases":232,"briefSummary":233,"conditions":234,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":45},"100644169","NCT07664995","Determining the Effects of Ischemic Conditioning and Neuromuscular Electrical Stimulation on Overall Function After Lower Limb Amputation","Improving Muscle Strength and Function After Lower Limb Amputation","Inclusion Criteria:\n\n* Older than 18 years old\n* History of unilateral transfemoral or transtibial amputation\n* Able to ambulate independently without the use of aids (i.e., walking cane)\n* Able to walk at least 6 minutes continuously without stopping.\n* Has a safe residuum with no open wounds on either the residual or intact limb\n* Has a prosthetic limb with materials that are sound and safe to withstand the mobility requirements of the study\n\nExclusion Criteria:\n\n* Younger than 18 years old\n* Inability to give informed consent\n* Neurological disorder such as multiple sclerosis that affects gait\n* Currently pregnant (or intend to become pregnant while participating in study)\n* Blood clots in the leg, or any condition in which compression of the thigh or transient ischemia is contraindicated (e.g. open wounds in the leg)\n* History of uncontrolled hypertension\n* History of heart failure\n* Implanted electrical device such as a pacemaker or defibrillator\n* Head injury within the previous 6 months\n* Seizure disorder\n* History of thrombosis\n* History of sickle cell trait\n* History of genetic disease that impacts gait (e.g. cerebral palsy, muscular dystrophy).",{"count":20,"type":21},[24],"The goal of this clinical trial is to learn if ischemic conditioning and neuromuscular electrical stimulation improves muscle strength and walking behavior in those with limb loss. The main questions this trial aims to answer are:\n\nDoes neuromuscular electrical stimulation improve muscle strength and gait behavior in people who have a leg amputation?\n\nDoes neuromuscular electrical stimulation boost the effects of ischemic conditioning on muscle strength and gait behavior in people who have a leg amputation?\n\nResearchers will compare the effects of neuromuscular electrical stimulation to ischemic conditioning to see if there are any significant differences between the impacts of each intervention. Also, researchers will use both interventions together to see if the interventions can boost each other's positive impacts on walking and function in people with leg amputation.\n\nParticipants will:\n\n* Do ischemic conditioning OR neuromuscular electrical stimulation OR both interventions at home every other day for 2 weeks\n* Visit the laboratory before and after completing interventions for the tests\n* Visit the laboratory one week after the post intervention visit for follow-up tests",[235,236],"Lower Limb Amputation Above Knee","Below Knee Amputation","2026-06-17",{"date":180,"type":37},{"date":240,"type":21},"2026-07-01",{"date":242,"type":21},"2027-12",{"name":43,"class":44},{"id":245,"slug":4,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":22,"phases":250,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":258,"completionDateStruct":259,"leadSponsor":261,"locationsCount":45},"100641190","NCT07596212","BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder","Inclusion Criteria:\n\n* Females 18 or older\n* Histologically-proven, resected, hormone receptor-positive (defined as estrogen receptor ≥1% and\u002For progesterone receptor (PgR)≥1% by immunohistochemistry at local institutions) early invasive breast cancer, stage I-III per American Joint Committee of Cancer (AJCC) 8th edition, regardless of Human Epidermal growth factor Receptor 2 (HER2) status\n* Completion of the following planned cancer treatments prior to registration:\n\n  * Surgical resection of breast and nodal surgery; (NOTE: Reconstructive surgery does not have to be completed)\n  * Adjuvant radiation therapy, if needed\n  * Neoadjuvant and\u002For adjuvant chemotherapy if needed\n  * Treatment with anti-HER2 agents is allowed\n* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.\n* Ability to swallow oral medication.\n* Provide written informed consent and fill out questionnaires\n* Willing to return to the enrolling institution for follow-up\n* Women of childbearing potential must not be pregnant or breastfeeding. A negative serum or urine pregnancy test is required per institutional practice guidelines. Women of childbearing potential will be required to use effective contraception from the time of consent until 30 days after the last dose of bupropion. Acceptable methods include hormonal contraception, intrauterine device, barrier methods with spermicide, or sterilization\n\nExclusion Criteria:\n\n* Previous bilateral oophorectomy or ovarian irradiation; pregnant or lactating at the time of randomization or desiring pregnancy within 5 years.\n* History of psychiatric illnesses on active treatment\n* History or active suicidal thoughts or behaviors\n* Currently taking anti-depressants, anti-anxiety, or anti-psychotic medications. History of seizure disorder\n* History of bulimia or anorexia nervosa\n* Inhibitors or inducers of CYP2B6\n* Drugs metabolized by CYP2D6\n* Use of monoamine oxidase inhibitors (MAOI)\n* History of hypertension, regardless of control status.\n* History of angle closure glaucoma\n* Subjects taking levodopa, amantadine, methylene blue, and linezolid\n* Those with a hypersensitivity to bupropion, anastrozole, letrozole, exemestane, goserelin, or leuprolide. Currently receiving any of the following cancer-directed therapies:\n\n  * Radiation therapy\n  * Systemic therapy such as chemotherapy (standard or investigational)\n  * Anti-HER2 agents are allowed",{"count":99,"type":21},[251,76],"PHASE1","This study is open to women who have early-stage breast cancer and are on aromatase inhibitor (AI) therapy, and who have hypoactive sexual desire disorder (HSDD). HSDD is a persistent lack of physical desire for sex and a lack of sexual activity, or even sexual thoughts or fantasies, that causes you distress. The researchers want to determine if sexual functioning, as measured by responses on a sexual functioning questionnaire, is improved by adding Bupropion Extended Release (XL) to the AI treatment regimen. Bupropion XL is an FDA-approved medication for the treatment of major depressive disorder, seasonal affective disorder, and nicotine dependence. It has been studied in HSDD in pre- and post-menopausal healthy women, and has been demonstrated to be effective, but it has not been thoroughly studied in women with early-stage breast cancer on AI therapy.",[217,254,255,58],"Hypoactive Sexual Desire Disorder","Hormone Receptor Positive Breast Carcinoma","2026-06-16",{"date":197,"type":37},{"date":134,"type":21},{"date":260,"type":21},"2031-07",{"name":43,"class":44},{"id":263,"slug":4,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":22,"phases":269,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":274,"startDateStruct":275,"completionDateStruct":276,"leadSponsor":278,"locationsCount":45},"100641343","NCT07581405","GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Cancer","Inclusion Criteria:\n\n* Age ≥ 18 years of age at time of consent\n* Eastern Cooperative Oncology Group (ECOG) score of 0-2\n* Histologically confirmed gastric adenocarcinoma, documented by biopsy.\n* Planned to receive neoadjuvant chemotherapy followed by surgical resection, as determined by the treating oncologist.\n* Demonstrates adequate organ function. All screening labs are to be obtained within 30 days prior to registration.\n* Able to provide written informed consent and HIPAA authorization for release of personal health information, via an approved UIC Institutional Review Board informed consent form and HIPAA authorization. If a subject is unable to consent, a Legally Authorized Representative (LAR) may provide consent on their behalf.\n* Women of childbearing potential must not be pregnant or breastfeeding. A negative serum or urine pregnancy test is required per institutional practice guidelines.\n* As determined at the discretion of the enrolling physician or protocol designee, the ability of the subject to understand and comply with study procedures for the entire length of the study\n\nExclusion Criteria:\n\n* Active infection requiring systemic therapy\n* Uncontrolled HIV\u002FAIDS or active viral hepatitis\n* Pregnant or nursing\n* Any prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of this investigational regimen, as determined by the treating medical oncologist.\n* Patients with a feeding tube (e.g., gastrostomy or jejunostomy) receive their primary source of nutritional intake via enteral tube feeding at the time of enrollment.\n* Any mental or medical condition that prevents the patient from giving informed consent or participating in the trial.\n* Other major comorbidity, as determined by the study PI",{"count":268,"type":21},26,[76],"This is a single-center, randomized, open-label clinical trial designed to evaluate the impact of low-dose olanzapine on weight loss, appetite, and nutritional outcomes in patients with gastric cancer receiving neoadjuvant chemotherapy. Eligible patients will be randomized to receive olanzapine 2.5 mg orally once daily (QD) in addition to standard neoadjuvant chemotherapy, beginning prior to initiation of chemotherapy and continuing until surgical resection. Patients will otherwise receive standard-of-care (SOC) oncologic treatment, with no alterations to chemotherapy regimens or surgical management. The study is designed to prospectively assess whether olanzapine improves appetite, mitigates weight loss, and enhances nutritional status and quality of life (QoL) during neoadjuvant therapy. This study will be conducted at the University of Illinois Cancer Center (UICC) as a single-site investigator-initiated trial, with an anticipated accrual of 26 participants over 2 years.",[272,273],"Gastric Adenocarcinoma","Gastric Cancer",{"date":197,"type":37},{"date":134,"type":21},{"date":277,"type":21},"2030-07",{"name":43,"class":44},{"id":280,"slug":4,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":285,"enrollmentInfo":286,"targetDuration":4,"studyType":22,"phases":287,"briefSummary":288,"conditions":289,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":45},"100641733","NCT07652970","Tele-CE in Severe Stroke","Effect of Home-based Cross-education on Lower Limb Neuroplasticity in Severe Stroke","Inclusion Criteria:\n\n* Single, monohemispheric stroke\n* Chronic stroke (\\> 6 months prior)\n* Severe stroke (Fugl-Meyer Lower Extremity motor scale score \\\u003C 21 or 6 Minute Walk Test distance \\\u003C 300m)\n\nExclusion Criteria:\n\n* Use of anti-spasticity medications\n* Existence of other neurological disorders\n* Have brainstem or cerebellar lesions.\n* Mini-Mental State Examiniation score of \\\u003C21, to ensure participants have the cognitive capacity to consent and can understand instructions both in-person and during remote supervision.\n* Non-English-speaking individuals\n* Bone, joint or soft tissue injury\n* Uncontrolled medical conditions (such as uncontrolled hypertension, untreated cardiac disease, or untreated pulmonary disease)\n* Unable to see the tablet and zoom screen\n* Unable to move non-paretic ankle (\\\u003C 5 degrees of ankle ROM)\n* Fugl-Meyer Lower Extremity sensory scale score \\\u003C 6\n\nTMS exclusion criteria\n\n* Previous adverse reaction to TMS\n* Skull abnormalities or fractures\n* Concussion within the prior 6 months\n* Unexplained, recurring headaches\n* Implanted cardiac pacemaker\n* Metal implants in the head or face\n* History of seizures or epilepsy\n* Use of medications that could alter cortical excitability or increase risk of seizure (e.g., antidepressants, antipsychotics, anxiolytics, anticonvulsants)\n* Current pregnancy\n\nPNS exclusion criteria\n\n* Skin hypersensitivity at any sites of stimulation, including the scalp, thoracolumbar spine, and peripheral limbs\n* History of contact dermatitis at any of the sites of stimulation\n* History of allodynia and\u002For hyperalgesia\n* Active skin infection\n* Skin lesions\n* Deep vein thrombosis\n* Any other skin or scalp condition that could be aggravated by stimulation\n* Implanted electronic, metallic, or highly conductive devices near site of stimulation that cannot be removed without permission from a health professional","80 Years",{"count":212,"type":21},[24],"The goal of this clinical trial is to determine the effects of home-based cross-education on lower limb neuroplasticity in severe stroke.\n\nThe main questions the investigators aim to answer are:\n\n* What are the effects of home-based cross-education on lower limb neuroplasticity?\n* What are the effects of home-based cross-education on lower limb function?\n* Is home-based cross-education feasible to administer and accepted by participants?\n\nParticipants will take part in ten home-based, remotely supervised sessions, during which participants will either perform unilateral skill and strength training of the unaffected lower limb (Tele-Cross Education or Tele-CE) or cognitive training and unilateral movements of the unaffected lower limb (Tele-control). Each participant will experience measures of brain and spinal activity and motor function testing before and after both sessions (Tele-CE and Tele-control). Each participant will also be asked to fill out a feedback questionnaire to assess acceptability after intervention sessions (Tele-CE and Tele-control).",[290],"Stroke","2026-06-11",{"date":237,"type":37},{"date":294,"type":21},"2026-06",{"date":296,"type":21},"2027-06",{"name":43,"class":44},{"id":299,"slug":4,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":304,"targetDuration":4,"studyType":22,"phases":306,"briefSummary":308,"conditions":309,"keywords":311,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":45},"100366208","NCT04048278","Lidocaine Infusion in Pancreatic Cancer","Lidocaine Infusion in Pancreatic Cancer: Translational Studies in a Preclinical Model And Human Subjects","Inclusion Criteria:\n\n1. Has histologically or cytologically confirmed adenocarcinoma of the pancreas that is considered resectable as well as other types of pancreatic cancer (malignant endocrine and exocrine tumors)\n2. Has measurable disease, defined as at least 1 tumor that fulfills the criteria\n3. Patients diagnosed with resectable cancer, but upon initial phase of surgical exploration found to have metastatic disease\n4. Has read, understood and signed the informed consent form (ICF) approved by the Independent Review Board\u002FIndependent Ethics Committee (IRB\u002FIEC)\n5. Prior systemic treatments for metastatic disease are permitted, including targeted therapies, biologic response modifiers, chemotherapy, hormonal therapy, or investigational therapy.\n\nExclusion Criteria:\n\n1. Has American Society of Anesthesiologists (ASA) physical status \\> 3\n2. Has hypersensitivity or allergy to amide-linked local anesthetics\n3. Has a second or third degree heart block\n4. Has severe sinoatrial block\n5. Is currently being treated with any of the following class I antiarrhythmic drugs; quinidine, flecainide, disopyramide, or procainamide\n6. Has been treated with amiodarone in the past\n7. Has Adams-Stoke syndrome\n8. Has Wolff-Parkinson-White syndrome\n9. Has a history of blood clots, pulmonary embolism, or deep vein thrombosis unless controlled by anticoagulant treatment\n10. Has a known history of human immunodeficiency virus (HIV) positivity or untreated and uncontrolled hepatitis B or C",{"count":305,"type":21},46,[307],"EARLY_PHASE1","This study elucidates the effects of the intravenous (IV) lidocaine infusion on the biology of pancreatic circulating tumor cells (CTCs) isolated from patients undergoing robotic pancreatectomy for all types of pancreatic cancer.\n\nA prospective randomized controlled double blinded trial design will be used for the proposed study.",[310],"Pancreatic Cancer",[312,310,313,314,315,316,317],"Pancreas","Lidocaine","Enzymatic Activity","Cytokines","Chemokines","Gene Expression",{"date":319,"type":37},"2026-06-15",{"date":321,"type":37},"2018-11-08",{"date":323,"type":21},"2028-01-01",{"name":43,"class":44},{"id":326,"slug":4,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":330,"eligibilityCriteria":331,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":332,"targetDuration":4,"studyType":22,"phases":334,"briefSummary":335,"conditions":336,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":4},"100642541","NCT07647432","HEME-25: Open-Label Feasibility Study of Elranatamab Utilized in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV","HEME-25: Open-Label Feasibility Study of Elranatamab Utilized in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV in Consolidation After Definitive Therapy","HEME-25","Inclusion Criteria:\n\n* Age ≥ 18 years at time of consent\n* ECOG performance status (PS) 0 or 1\n* Histologically and immunophenotypically confirmed PBL\n* Ann Arbor stage at initial diagnosis: stage I with lactate dehydrogenase (LDH) \\> upper limit of normal (ULN) and\u002For bulky disease \\>7.5 cm or stage II-IV\n* Received definitive front-line therapy for PBL with end-of-treatment PR or CR\n* Adequate bone marrow function with recovery from prior therapy, defined as:\n\n  * ANC ≥ 500 cells\u002FmcL\n  * Platelet count ≥ 50,000 cells\u002FmcL\n* Availability of archival tumor tissue (block or unstained slides) for mandatory central pathology review and correlative BCMA testing. Central pathology review and BCMA testing may be completed after enrollment.\n* Able to provide written informed consent and HIPAA authorization for release of personal health information, via an approved UIC Institutional Review Board (IRB) informed consent form and HIPAA authorization. If a subject is unable to consent, a LAR may provide consent on their behalf.\n* As determined at the discretion of the enrolling physician or protocol designee, the ability of the subject to understand and comply with study procedures for the entire length of the study\n* If capable of becoming pregnant: Negative serum or urine pregnancy test\n* If HIV-positive:\n\n  * Receiving effective combined antiretroviral therapy\n  * CD4+ T-cell count ≥ 50 cells\u002FmcL within 4 weeks before enrollment\n\nExclusion Criteria:\n\nKey inclusion criteria:\n\n* Age ≥ 18 years at time of consent\n* ECOG performance status (PS) 0 or 1\n* Histologically and immunophenotypically confirmed PBL\n* Ann Arbor stage at initial diagnosis: stage I with lactate dehydrogenase (LDH) \\> upper limit of normal (ULN) and\u002For bulky disease \\>7.5 cm or stage II-IV\n* Received definitive front-line therapy for PBL with end-of-treatment PR or CR\n* Adequate bone marrow function with recovery from prior therapy, defined as:\n\n  * ANC ≥ 500 cells\u002FmcL\n  * Platelet count ≥ 50,000 cells\u002FmcL\n* Availability of archival tumor tissue (block or unstained slides) for mandatory central pathology review and correlative BCMA testing. Central pathology review and BCMA testing may be completed after enrollment.\n* Able to provide written informed consent and HIPAA authorization for release of personal health information, via an approved UIC Institutional Review Board (IRB) informed consent form and HIPAA authorization. If a subject is unable to consent, a LAR may provide consent on their behalf.\n* As determined at the discretion of the enrolling physician or protocol designee, the ability of the subject to understand and comply with study procedures for the entire length of the study\n* If capable of becoming pregnant: Negative serum or urine pregnancy test\n* If HIV-positive:\n\n  * Receiving effective combined antiretroviral therapy\n  * CD4+ T-cell count ≥ 50 cells\u002FmcL within 4 weeks before enrollment\n\nKey exclusion criteria:\n\n* Prior BCMA bispecific therapy\n* Stable or progressive disease following front-line therapy as determined by the investigator\n* Receiving any other investigational agents\n* Expected survival \\\u003C 2 months\n* Known or suspected PBL involvement of the parenchymal brain or spinal cord at diagnosis. Asymptomatic leptomeningeal disease only will be allowed.\n* Uncontrolled intercurrent illness, including but not limited to uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Concurrent malignancy requiring active therapy within the last 3 years, except for the following:\n\n  * Basal cell carcinoma limited to the skin\n  * Squamous cell carcinoma limited to the skin\n  * Carcinoma in situ of the cervix or breast\n  * Adequately treated lentigo malignant melanoma\n  * Localized prostate cancer\n  * Active therapy consists of adjuvant or maintenance therapy to reduce the risk of recurrence of a malignancy that was previously treated with curative intent and with no evidence of active disease within 2 years prior to screening\n* Pregnant or nursing\n* PWH with a history of AIDS-defining opportunistic infection within the past year\n* Receipt of a live vaccine within 28 days prior to the first dose of study treatment",{"count":333,"type":21},17,[76,55],"This is a single-arm feasibility trial in which patients with histologically confirmed plasmablastic lymphoma (PBL) with or without HIV, who have achieved a Complete Response or Partial Response after definitive frontline chemotherapy, will receive Elranatamab (Elra) consolidation.",[337,338,339],"Plasmablastic Lymphoma","Hiv","Consolidation","2026-06-09",{"date":319,"type":37},{"date":343,"type":21},"2026-12-01",{"date":345,"type":21},"2030-12-01",{"name":43,"class":44},{"id":348,"slug":4,"hasResults":11,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":352,"eligibilityCriteria":353,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":285,"enrollmentInfo":354,"targetDuration":4,"studyType":22,"phases":356,"briefSummary":357,"conditions":358,"keywords":361,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":45},"100625872","NCT07428278","Resilience-Building for Advance Care Planning","Facilitating Advance Care Planning Discussions Between Patients With Advanced Cancer and Their Family Caregivers Using a Resilience-Building Intervention: A Randomized Controlled Trial.","ROCKS","Inclusion Criteria:\n\n* Eligible patients will (1) be ≥ 18 years of age; (2) be diagnosed with stage 3 or 4 cancer; and (3) have a family caregiver who is willing to participate.\n* Eligible family caregivers will be ≥ 18 years of age. All participants must be able to read, write, and speak English with minimal assistance from others and have access to the internet on a smartphone, laptop, or computer.\n\nExclusion Criteria:\n\n* Patient participants will be ineligible if they have (1) a Short Portable Mental Status Questionnaire (SPMSQ) score \\\u003C 8; or (2) have completed any form of advance directive.",{"count":355,"type":21},152,[24],"The aims of this study are to (1) assess the feasibility, acceptability, and usability of the ROCKS intervention among patients with advanced cancer and their family caregivers through a randomized controlled trial in a cancer center setting; (2) evaluate the preliminary efficacy of ROCKS, as compared to usual care, on changes in completion of advance directives; and (3) explore the dyadic effects of resilience on self-efficacy, optimism, dyadic communication and coping, anxiety, and depression using an actor-partner interdependence model.",[359,360],"Advanced Cancer","End of Life",[362,363],"Resilience","Advance Care Planning","2026-06-05",{"date":340,"type":37},{"date":367,"type":37},"2026-05-28",{"date":369,"type":21},"2028-07-31",{"name":43,"class":44},{"id":372,"slug":4,"hasResults":11,"nctId":373,"briefTitle":374,"officialTitle":374,"acronym":375,"eligibilityCriteria":376,"healthyVolunteers":11,"sex":17,"minAge":97,"maxAge":4,"enrollmentInfo":377,"targetDuration":4,"studyType":22,"phases":378,"briefSummary":379,"conditions":380,"keywords":382,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":45},"100562426","NCT06603012","Behavioral Intervention for Lifestyle Physical Activity in Parkinson's Disease","LifePD","Inclusion Criteria:\n\n* confirmed diagnosis of PD\n* Internet and email access\n* willingness to complete the cognitive assessments and questionnaires, wear the accelerometer, and undergo randomization\n* insufficient physical activity (i.e., not meeting current physical activity guidelines) based on a health contribution score of less than 14 units from the Godin Leisure-Time Exercise Questionnaire\n* self-reported ability to ambulate without assistance\n* age of 50+ years\n* English as a primary language\n* asymptomatic (i.e., one or fewer affirmatives on the Physical Activity Readiness Questionnaire \\[PAR-Q\\]) or physician approval for undertaking exercise training for those with 2 or more affirmatives on the PAR-Q\n\nExclusion Criteria:\n\n* above inclusion criteria not met\n* moderate or high risk of contraindications for possible injury or death when undertaking strenuous or maximal exercise using the PAR-Q\n* severe cognitive impairment that might preclude compliance with the conditions based on a modified Telephone Interview for Cognitive Status (TICS-M) score of less than 18\n* normal cognitive impairment based on the Montreal Cognitive Assessment (MoCA) score of 26 or more for avoiding ceiling effects involving change in cognitive function",{"count":192,"type":21},[24],"The investigators propose a Stage-I randomized controlled trial (RCT) of a remotely-delivered, 16-week social-cognitive theory-based behavioral intervention focusing on combined exercise (aerobic and resistance) training for yielding increases in device-measured physical activity and improvements in cognitive function, symptoms, and quality of life (QOL), and social-cognitive theory (SCT) outcomes among physically inactive persons with Parkinson's disease (PD). Participants (N=50) will be randomly assigned into exercise training (combined aerobic and resistance exercise) condition or active control (flexibility and stretching) condition. The 16-week intervention will be delivered and monitored remotely within a participant\\'s home\u002Fcommunity and supported by Zoom-based chats guided by SCT via a behavioral coach. Participants will receive training materials (e.g., prescriptive manual and exercise equipment), one-on-one coaching, action-planning via calendars, self-monitoring via logs, and SCT-based newsletters. The investigators hypothesize that the home-based exercise intervention will yield improvements in cognitive, symptomatic, and QOL outcomes.",[381],"Parkinson Disease (PD)",[383,384,385,386,387,388,389,390,32,391,29,392],"Parkinson disease","Parkinsonian disorders","Movement disorders","Basal ganglia diseases","Brain diseases","Nervous system diseases","Central nervous system diseases","Neurodegenerative diseases","Walking","Physical Activity","2026-06-02",{"date":395,"type":37},"2026-06-04",{"date":397,"type":21},"2026-08",{"date":399,"type":21},"2027-08",{"name":43,"class":44},{"id":402,"slug":4,"hasResults":11,"nctId":403,"briefTitle":404,"officialTitle":404,"acronym":405,"eligibilityCriteria":406,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":407,"enrollmentInfo":408,"targetDuration":4,"studyType":22,"phases":410,"briefSummary":411,"conditions":412,"keywords":414,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":419,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":45},"100443224","NCT05051618","Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis","METS in MS","Inclusion Criteria\n\n* Physical confirmed diagnosis of Multiple Sclerosis (MS)\n* Diagnosis of Major Depressive Disorder (MDD) - see below (MINI)\n* English as primary language\n* Eligible age (between 18 and 64 years old)\n* Relapse and steroid free in past 30 days\n* Internet and email access\n* Willingness to complete the testing and questionnaires, wear the accelerometer, undergo randomization, and engage in exercise testing\n\nExclusion Criteria\n\n* Godin Leisure Time Exercise Questionnaire (GLTEQ): Exclude if health contribution score of 14 units or more. This assessment is administered to confirm insufficient baseline physical activity (i.e., not meeting current PA guidelines)\n* Patient Determined Disease Steps (PDDS): Exclude if score above '2' (i.e., greater than mild ambulatory disability). This assessment is administered as the proposed intervention focuses on walking as main modality for exercise training. The scale asks the participant to describe their walking situation on a scale of 0 to 8; where lower scores indicate better walking ability.\n* Beck Depression Inventory-Fast Screen (BDI-FS): Exclude if a score less than '4'. The scale measures depression and those with a score of '4' or below likely have very mild depression resulting in floor effects and\u002For spontaneous remission.\n* Physical Activity Readiness Questionnaire (PAR-Q): Exclude if more than one yes\u002Faffirmative response on this 7-item self-report assessment. This assessment is administered to exclude those individuals who are at a moderate to high risk for contraindications of injury or possible death when undertaking strenuous or maximal exercise. This is a 7-item self-report tool where more than one yes\u002Faffirmative response indicates that an individual is not recommended to engage in physical activity within the capacity of this study. Those scoring more than one yes\u002Faffirmative response will be further advised to seek medical guidance before becoming more physically active.\n* Telephone Interview for Cognitive Status (TICS-M): Exclude if scores less than 18. This assessment is administered to ensure that all participants can adequately follow directions. The application of the TICS-M is to ensure that participants do not have severe cognitive impairment that might preclude the ability to adhere to the conditions, understand intervention content, and interact with behavior coaches.\n* MINI International Neuropsychiatric Interview (version 7.0.2) based on the Diagnostic and Statistical Manual of Mental Disorders V (DSM-V): Include those who meet the criteria for MDD, but exclude for other severe mental illness (obsessive-compulsive disorder, schizophrenia, bipolar or other psychotic disorders) as indicated by the MINI; these persons would require more intensive mental health treatment.","64 Years",{"count":409,"type":21},146,[24],"The purpose of this research is to examine the effects of two different exercise training regimens for managing depression and improving other health indicators among persons with multiple sclerosis (MS). The project will enroll persons with MS and major depressive disorder (MDD) between 18 and 64 years of age. The investigators will enroll a total of 146 participants.\n\nThis is a Phase-II trial that compares the efficacy of an exercise training program (POWER-MS) compared with a stretching program (FLEX-MS) for immediate and sustained reductions in the severity of depression among persons with MS who have MDD.",[27,413],"Major Depressive Disorder",[27,415,79,416,29,392,417,418],"MS","MDD","Intervention","Behavior",{"date":395,"type":37},{"date":421,"type":37},"2023-04-01",{"date":423,"type":21},"2026-10-31",{"name":43,"class":44},{"id":426,"slug":4,"hasResults":11,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":4,"eligibilityCriteria":430,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":431,"targetDuration":4,"studyType":22,"phases":433,"briefSummary":434,"conditions":435,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":45},"100472116","NCT05427695","Topical Probiotic Sinus Irrigations for Treating Chronic Sinusitis","Topical Probiotic Sinus Irrigations for the Treatment of Chronic Rhinosinusitis: a Double Blinded Randomized Controlled Trial","Inclusion Criteria:\n\n1. Male and female patients 18 years of age or older.\n2. Patients diagnosed with acute exacerbation of CRS, defined by worsening of 1 or more sinonasal symptoms (nasal obstruction\u002Fcongestion, nasal discharge, facial pain\u002Fpressure, reduced sense of smell) and inflammatory and\u002For infectious changes on sinus endoscopy.\n3. Patients that have undergone functional endoscopic sinus surgery \\> 12 months prior to enrollment as documented in the patients electronic medical record, with patent sinuses deemed suitable for trial on investigator's discretion.\n4. Patients must be willing to follow study related procedures for the duration of the study.\n5. Patients must understand the purpose and procedures and be willing to sign the study informed consent document.\n6. All adult men and women with active CRS will be considered for participation in this study without regard to race, gender, or socioeconomic status.\n\nExclusion Criteria:\n\n1. Patients who are taking topical antibiotic irrigations and are unwilling to stop them.\n2. Patients who are unable to complete self-administered questionnaires because of cognitive impairment, language barrier, or severe medical conditions.\n3. Patients who have a terminal illness (malignancy), immunocompromised (medication-related immunosuppression, immunodeficiency disorder) or systemic disease (granulomatosis polyangiitis or other autoimmune disease with sinonasal manifestations, cystic fibrosis), or recent head\u002Fsinonasal trauma that may predispose to infectious complications.\n4. Patients who have severe or emergent complications from CRS or presence of a sinus tumor.\n5. Female patients who are pregnant or breastfeeding. The patient will be asked if she is pregnant or has any chance of being pregnant. In either case, the patient will be excluded. Note in our consent form this is also addressed (excerpt below).\n6. Patients who are taking oral corticosteroids or who have taken oral antibiotics in the previous 2 weeks or on oral corticosteroids.\n7. Patients who have upper respiratory infection-type symptoms at time of enrollment, e.g., fevers\u002Fchills, sneezing, runny nose, sore throat, coughing. Patients can be eligible for enrollment once symptoms have fully resolved if all other inclusion\u002Fexclusion criteria are met.",{"count":432,"type":21},60,[76],"The purpose of this randomized study will be to determine whether topical probiotic sinus irrigations are more effective compared to saline sinus irrigation controls in the treatment of active CRS in patients who have had prior sinus surgery based on subjective and objective outcome measures.",[436],"Chronic Rhinosinusitis (Diagnosis)","2026-05-21",{"date":439,"type":37},"2026-05-27",{"date":441,"type":37},"2025-02-05",{"date":443,"type":21},"2028-07-30",{"name":43,"class":44},{"id":446,"slug":4,"hasResults":11,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":450,"eligibilityCriteria":451,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":452,"enrollmentInfo":453,"targetDuration":4,"studyType":22,"phases":455,"briefSummary":456,"conditions":457,"keywords":459,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":45},"100435986","NCT04957355","Effect of NMES on Balance and Fall Risk in Chronic Stroke","Effect of Neuromuscular Electrical Stimulation (NMES) on Reactive Balance, Gait and Fall-risk in Individuals With Stroke","NMES","Inclusion Criteria:\n\nAge group: 18-90 years.\n\n1. Presence of hemiparesis.\n2. Onset of stroke (\\> 6 months).\n3. Ability to walk independently with or without an assistive device for at least 300 ft.\n4. Can understand and communicate in English.\n5. Cognitively and behaviorally capable of complying with the regimen (Montreal Cognitive Assessment \\> 25\u002F30).\n\nExclusion Criteria:\n\nSubjects will not proceed with the test if any of the following occurs at baseline measurement: 1) HR \\> 85% of age-predicted maximal heart rate (HRmax) (HRmax = 220 - age), 2) systolic blood pressure (SBP) \\> 165 mmHg and\u002For diastolic blood pressure (DBP) \\> 110 mmHg during rest, or 3) oxygen saturation (measured by pulse oximeter) \\\u003C 95% during rest.\n\n1. Body weight more than 250 lbs.\n2. Any neurological condition other than stroke.\n3. Any cardiopulmonary, musculoskeletal, or systemic diagnosis.\n4. Recent major surgery (\\\u003C 6 months) or hospitalization (\\\u003C 3 months).\n5. Deep venous thrombosis.\n6. Antecedent of cancer.\n7. Peripheral nerve injury or neuropathy in the affected limb with motor disability.\n8. Spasticity (Ashworth scale \\> 2).\n9. Uncontrolled high blood pressure\u002Fangina.\n10. Skin condition not tolerant with FES therapy.\n11. Uncontrolled seizure disorder.\n12. Botox treatment within the last 5 months.\n13. History of epilepsy.\n14. Pacemaker users.\n\nExcluded or Vulnerable Populations Non-English speaking populations will be excluded as the consent procedures and instructions will be in English.","90 Years",{"count":454,"type":21},20,[24],"The aim of this study is to describe the effect of neuromuscular electrical stimulation (NMES) in the form of functional electrical stimulation (FES) applied to different lower limb muscles on reactive balance and gait performance in stroke participants.\n\nMethods: Twenty individuals with chronic stroke will be asked to perform an experimental protocol that includes a postural disturbance in the form of a slip- or trip-like perturbation and a standardized walking test in both laboratory and outdoor environments with and without FES applied to different lower limb muscles of the paretic leg. FES will be applied using an advanced software that is able to synchronize muscle activation with the time of perturbation onset and according to the phases of gait.\n\nThis project design aims to examine whether a specific pattern of lower limb muscle stimulation could improve the kinematic and behavioral responses during reactive balance following slip- and trip-like perturbations. Additionally, the project aims to see if the kinematic and spatio-temporal gait parameters can be modified during a standardized walking test under different sensory and environmental conditions.",[458],"Chronic Stroke",[460,461,462,463,464,465,466,467],"functional electrical stimulation","neuromuscular electrical stimulation","walk-training","treadmill training","reactive balance","perturbation","falls","fall prevention","2026-05-20",{"date":470,"type":37},"2026-05-22",{"date":472,"type":37},"2021-05-15",{"date":474,"type":21},"2027-11-30",{"name":43,"class":44},{"id":477,"slug":4,"hasResults":11,"nctId":478,"briefTitle":479,"officialTitle":479,"acronym":4,"eligibilityCriteria":480,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":285,"enrollmentInfo":481,"targetDuration":4,"studyType":22,"phases":482,"briefSummary":483,"conditions":484,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":493,"locationsCount":45},"100538513","NCT06291818","Self-Adhering Magnetic Device to Treat Corneal Exposure","Inclusion Criteria:\n\n* Males and females ages 18-80 years old.\n* Patients with recent corneal abrasion and no signs of infection in the examination\n* Patients with lagophthalmos\n* Normal Controls\n\nExclusion Criteria:\n\n* Individuals with adhesive or tape allergies.\n* Individuals with a history of metal pieces\u002Fshavings embedded in the eye (such as from welding or metalworking)\n* Individuals with eye infections",{"count":7,"type":21},[24],"Paralytic lagophthalmos can be difficult to treat and manage. It has a host of causes and effects, one of which (for the latter) is exposure keratopathy. Untreated, this can lead to corneal ulceration, inflammation, and potentially blindness. Despite a variety of attempts at treating this complex condition, none have satisfactorily reduced complications ranging from ease of use to aesthetics. With improvement in magnetic technology, however, that may change. Barmettler et al (2014) have demonstrated preliminary success of externally affixed magnets in closing both model and patient eyelids. As such, we hypothesize that magnetic devices can be used to treat corneal exposure by controlling eyelid position.",[485,486],"Paralytic Lagophthalmos","Corneal Exposure","2026-05-18",{"date":470,"type":37},{"date":490,"type":37},"2024-04-17",{"date":492,"type":21},"2027-09-01",{"name":43,"class":44},{"id":495,"slug":4,"hasResults":11,"nctId":496,"briefTitle":497,"officialTitle":497,"acronym":498,"eligibilityCriteria":499,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":72,"enrollmentInfo":500,"targetDuration":4,"studyType":22,"phases":501,"briefSummary":502,"conditions":503,"keywords":506,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":510,"startDateStruct":512,"completionDateStruct":514,"leadSponsor":516,"locationsCount":45},"100606399","NCT07175051","Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin","EMPA-CKD","Inclusion Criteria:\n\n* Documentation of SCA genotype (HbSS or HbSβ0-thalassemia)\n* Albuminuria defined by a UACR of 100 - 2,000 mg\u002Fg creatinine at the screening\n* Hemoglobin (Hb) ≥ 5.5 g\u002FdL during screening\n* For participants taking Endari, the dose of Endari must be stable for at least one month prior to signing the ICF and with no anticipated need for dose adjustments during the study\n* For participants on crizanlizumab or chronic red blood cell transfusions, the therapy must have started at least 3 months prior to consent\n* For participants taking an angiotensin converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB), the dose must be stable for at least 3 months prior to signing the ICF and with no anticipated need for dose adjustments during the study, in the opinion of the Investigator\n* Participants must demonstrate regular compliance with clinic visits and outpatient management\n* Participants, if female and of childbearing potential, will use highly effective methods of contraception from study start to 30 days after the last dose of the study drug\n* Participant has provided documented informed consent or assent\n\nExclusion Criteria:\n\n* Concurrent diagnosis of diabetes mellitus\n* Female who is breast feeding, pregnant, or unwilling to use birth control as described in the protocol\n* Prior hypersensitivity or intolerance to a sodium-glucose cotransporter-2 inhibitor (SGLT2i)\n* Active or open leg ankle ulcer\n* Chronic urinary tract infection\n* Hospitalized for sickle cell crisis or other vaso-occlusive event within 14 days prior to signing consent\n* Hepatic dysfunction characterized by alanine aminotransferase (ALT) \\>5× ULN\n* Participants with acute bacterial infection requiring antibiotic use should delay screening\u002Fenrollment until the course of antibiotic therapy has been completed\n* Participants with known active hepatitis A, B, or C or who are known to be human immunodeficiency virus (HIV) positive\n* Moderate to severe CKD (defined by an eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m2, on chronic dialysis, or having received a kidney transplantation)\n* History of malignancy within the past 2 years prior to treatment Day 1 requiring chemotherapy and\u002For radiation (with the exception of local therapy for non-melanoma skin malignancy)\n* History of unstable or deteriorating cardiac or pulmonary disease within 6 months prior to consent including but not limited to the following:\n\n  1. Unstable angina pectoris or myocardial infarction or elective coronary intervention\n  2. Uncontrolled clinically significant arrhythmias\n* Any condition affecting drug absorption, such as major surgery involving the stomach (e.g. bariatric surgery) or small intestine (prior cholecystectomy is acceptable)\n* Participated in another clinical trial of an investigational agent (or medical device) within 30 days or 5 half-lives of agent, whichever is longer, or is currently participating in another trial of an investigational agent or medical device)\n* Medical, psychological, or behavioral conditions, which, in the opinion of the Investigator, may preclude safe participation, confound study interpretation, interfere with compliance, or preclude informed consent\n* Contraindication to MRI (certain pacemakers, electronic implants, shrapnel in the eyes, or certain intracranial aneurysm clips)",{"count":454,"type":21},[76],"Sickle cell anemia (SCA) is an inherited red blood disorder. The kidneys are among the most commonly affected organ systems in SCA. The Food and Drug Administration (FDA) has approved empagliflozin as a treatment to reduce the decline of kidney function in those with kidney disease. The proposed research study aims to determine whether empagliflozin can prevent the progression of kidney dysfunction in patients with sickle cell anemia (SCA) who are at high risk of developing advanced chronic kidney disease (CKD).",[504,505],"Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)","Albuminuria",[507,508],"Empa-CKD","Sickle Cell-Related Kidney Disease","2026-05-15",{"date":511,"type":37},"2026-05-19",{"date":513,"type":37},"2026-04-08",{"date":515,"type":21},"2030-10",{"name":43,"class":44},{"id":518,"slug":4,"hasResults":11,"nctId":519,"briefTitle":520,"officialTitle":521,"acronym":4,"eligibilityCriteria":522,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":523,"targetDuration":4,"studyType":22,"phases":525,"briefSummary":526,"conditions":527,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":45},"100638789","NCT07588542","PACU Discharge Readiness","Development of Assessment Tools for Determining Outpatient Subjects' Home-Readiness After Receiving Anesthesia (Without Family or Friend to Drive Them Home)","Inclusion Criteria:\n\n* The individuals will be identified from the operating room (OR) schedule and approached in the pre-operative area (or earlier, when possible).\n* Adult patients (18 years or older) listed for surgery and a planned 23-hour admission will be eligible for enrollment in this study.\n* Subjects must be fluent in English and not have confounding sensory or neurological limitations to participation\n\nExclusion Criteria:\n\n* Members of vulnerable populations or adults unable to consent will be included in this study.\n* Subjects that do not speak English\n* Subjects with neurological limirations",{"count":524,"type":21},1000,[24],"The use of custom-created apps, neuropsychological testing, and clinical assessments will be evaluated as tools for determining the appropriateness of PACU discharge to home.",[528,529,530],"Patient Discharge","Neurocognition","Baseline","2026-05-08",{"date":533,"type":37},"2026-05-14",{"date":535,"type":21},"2026-05-01",{"date":537,"type":21},"2032-04-01",{"name":43,"class":44},{"id":540,"slug":4,"hasResults":11,"nctId":541,"briefTitle":542,"officialTitle":543,"acronym":4,"eligibilityCriteria":544,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":545,"targetDuration":4,"studyType":22,"phases":546,"briefSummary":547,"conditions":548,"keywords":549,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":551,"startDateStruct":553,"completionDateStruct":555,"leadSponsor":557,"locationsCount":45},"100399142","NCT04477330","Cortical Priming to Optimize Gait Rehabilitation in Stroke: a Renewal","Cortical Priming to Optimize Gait Rehabilitation: Renewal","Inclusion Criteria:\n\n* Age greater than 18 years\n* First ever monohemispheric stroke \\> 3 months since onset\n* Residual hemiparetic gait deficits (e.g. abnormal gait pattern)\n* Able to walk for 5 minutes at self-paced speed. Handheld assistive device is acceptable.\n* Walking speed lesser than 1.2 m\u002Fs\n* Lower limb Fugl-Meyer Motor score between 15-30\n* At least 5 deg of ankle dorsiflexion necessary to perform the ankle-tracking task\n\nExclusion Criteria:\n\n* General exclusion criteria\n\n  * Severe osteoporosis\n  * Contracture-limiting range of motion of lower limb\n  * Score of more than 2 on the Modified Ashworth Scale (indicating increased muscle tone through ankle range of motion)\n  * Uncontrolled anti-spasticity medications during the study period\n  * Score less than 6 on the Fugl-Meyer Sensory Assessment Scale for the Lower Limb\n  * Cardiorespiratory or metabolic diseases (e.g. cardiac arrhythmia, uncontrolled hypertension or diabetes, chronic emphysema)\n  * Unhealed decubiti, persistent infection\n  * Significant cognitive or communication impairment (Mini-Mental State Examination (MMSE)\\\u003C21), which could impede the understanding of the purpose of procedures of the study or prevent the patient from performing the ankle-tracking task.\n  * Lesions involving the brainstem and cerebellum\n  * Failure to pass the graded exercise stress test\n\nTMS exclusion criteria\n\n* Implanted cardiac pacemaker\n* Metal implants in the head or face\n* Unexplained, recurring headaches\n* History of seizures or epilepsy\n* Currently under medication that could increase motor excitability and lower seizure threshold\n* Skull abnormalities or fractures\n* Concussion within the last 6 months\n* Currently pregnant\n\ntDCS exclusion criteria\n\n* Skin hypersensitivity\n* History of contact dermatitits\n* History of allodynia and\u002For hyperalgesia\n* Any other skin or scalp condition that could be aggravated by tDCS",{"count":99,"type":21},[24],"Achieving functional ambulation post stroke continues to be a challenge for stroke survivors, clinicians, and researchers. In the effort to enhance outcomes of motor training, cortical priming using brain stimulation has emerged as a promising adjuvant to conventional rehabilitation. This project focuses on the development of a long term gait rehabilitation protocol using brain stimulation to improve walking outcomes in people with stroke. The project will also aim to understand the neural mechanisms that are associated with response to the intervention.",[290],[550,391],"tDCS",{"date":552,"type":37},"2026-05-11",{"date":554,"type":37},"2020-09-01",{"date":556,"type":21},"2027-08-31",{"name":43,"class":44},{"id":559,"slug":4,"hasResults":11,"nctId":560,"briefTitle":561,"officialTitle":562,"acronym":563,"eligibilityCriteria":564,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":565,"enrollmentInfo":566,"targetDuration":4,"studyType":22,"phases":568,"briefSummary":569,"conditions":570,"keywords":572,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":576,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":581,"locationsCount":45},"100609920","NCT07220850","Oral Health Intervention for Caregivers of Children Presenting for Dental Surgery","Testing a Multi-behavioral Intervention to Improve Oral Health Behaviors in the Pediatric Dental Surgery Population","PROTECT","Inclusion Criteria:\n\n* caregivers of child patients who are in the same household greater than or equal to 50% of the week\n* caregivers aged 18-90 years\n* caregivers with access to a computer or a telephone\n* child patients that are less than 96 months of age at the time of enrollment scheduled for DGA at the UIC clinic\n\nExclusion Criteria:\n\n* surgical child is foster status\n* families who are planning to move out of state within the six-month period\n* children with systemic health issues as classified by American Society of Anesthesiology Classification of greater than or equal to 3, or a mental health condition such as autism\u002Fdevelopmental delay, as medical complexity is associated with other issues that influence a child's health behaviors and caregiver-child interactions\n* and adults unable to consent.","7 Years",{"count":567,"type":21},420,[24],"Too many young children, particularly those living in poverty, present for dental surgery under anesthesia - an expensive, potentially dangerous, short-term fix that often results in recurring oral health disease and subsequent surgeries. Dr. Helen Lee, an anesthesiologist, and Dr. Joanna Buscemi, a clinical health psychologist, recognized that to decrease need for surgeries, caregivers need resources and support to build their skills and knowledge around managing their child's oral health. After 5 years of relationship-building, publishing preliminary qualitative work, and building a team with the appropriate skills and knowledge, investigators developed a grant application to develop and test a parenting intervention for caregivers of preschool- aged children presenting for dental surgery.\n\nWith support from the National Institute of Dental and Craniofacial Research (NIDCR) of the National Institutes of Health (NIH), the team created the PROTECT intervention with a focus on providing caregivers with parenting and behavioral tools to help improve tooth brushing and lower added sugar intake while simultaneously addressing social determinants of health that make behavior change more difficult. Community health workers will engage with caregivers for 6 months following the child's surgery to deliver PROTECT and support parents in behavioral change. A surgical event is a unique opportunity to change behaviors in systemically oppressed families that have manifested a need for behavior change. This intervention will meet caregivers needs at a critical time when risk disease recurrence intersects with a desire to change. This work has the potential to not only improve oral health of entire households but may also have a concomitant effect on parallel diseases, such as pediatric obesity.",[571],"Early Childhood Caries",[571,573,574],"Behavioral Intervention","Community Health Workers","2026-05-07",{"date":531,"type":37},{"date":578,"type":37},"2025-09-30",{"date":580,"type":21},"2028-09",{"name":43,"class":44},""]